Correlation analysis of FABP3, MCP-4, and CXCL9 levels and myocardial damage in patients with severe pneumonia
FABP3, MCP-4, and CXCL9 levels in myocardial damage of severe pneumonia
Abstract
[Objective] To explore the correlations between the levels of serum monocyte chemoattractant protein-4 (MCP-4), heart-type fatty acid binding protein (FABP3), and chemokine ligand 9 (CXCL9) and myocardial damage in severe Mycoplasma pneumoniae (SMPP) patients. [Methods] A total of 158 patients with severe Mycoplasma pneumoniae complicated with myocardial damage were included in the SMPP group. They were divided into a myocardial damage group (n=42) and a nonmyocardial damage group (n=116) according to whether myocardial damage occurred. The control group consisted of an additional 102 healthy people who were examined throughout the same time period. The levels of serum MCP-4, FABP3 and CXCL9 in the two groups were compared. The general clinical data of the patients were recorded. Multivariate logistic analysis was conducted to analyze the risk factors for myocardial damage in patients with severe mycoplasma complicated with pneumonia.
[Results] The levels of serum MCP-4, FABP3 and CXCL9 in the SMPP group were significantly greater (all P<0.05). Compared with those in the nonmyocardial damage group, Serum MCP-4, FABP3, and CXCL9 levels were considerably higher (all P<0.05) in the group with myocardial injury. Age, sex, diabetes, smoking history, hypoxemia, jaundice, and chronic obstructive pulmonary disease (COPD) did not differ statistically significantly between the two groups (all P>0.05). Compared with those in the nonmyocardial damage group, the proportions of patients with hypertension, coronary heart disease and anemia, as well as the levels of serum MCP-4, FABP3 and CXCL9, in the myocardial damage group were significantly greater (all P<0.05). Combined hypertension, coronary heart disease, anemia, and high levels of serum MCP-4, FABP3, and CXCL9 are risk factors for myocardial damage in patients with severe mycoplasma infection. The levels of serum MCP-4, FABP3 and CXCL9 in patients were positively correlated with the incidence of myocardial damage in patients with severe mycoplasma infection (all P<0.05). [Conclusion] The levels of serum MCP-4, FABP3 and CXCL9 are positively correlated with myocardial damage in patients with severe Mycoplasma pneumoniae. Moreover, combined hypertension, coronary heart disease, anemia and high levels of serum MCP-4, FABP3 and CXCL9 are risk factors for myocardial damage in patients with severe mycoplasma infection. These three factors can be used as biological indicators of myocardial damage in patients with severe mycoplasma infection in clinical practice and are highly important for the assessment of patients' conditions and the formulation of treatment plans.
References
2.Ni T, Zhao F. Predicting myocardial damage in children with mycoplasma pneumoniae pneumonia: a retrospective case‒control study. BMC Infect Dis. 2025 May 22;25(1):733. doi: 10.1186/s12879-025-11132-w. PMID: 40405087; PMCID: PMC12100917.
3.He B, Li X, Dong R, Yao H, Zhou Q, Xu C, Shang C, Zhao B, Zhou H, Yu X, Xu J. Development of machine learning-based differential diagnosis model and risk prediction model of organ damage for severe Mycoplasma pneumoniae pneumonia in children. Sci Rep. 2025 Mar 19;15(1):9431. doi: 10.1038/s41598-025-92089-3. PMID: 40108182; PMCID: PMC11923196.
4.Qiu J, Ge J, Cao L. D-dimer: The Risk Factor of Children's Severe Mycoplasma Pneumoniae Pneumonia. Front Pediatr. 2022 Apr 12;10:828437. doi: 10.3389/fped.2022.828437. PMID: 35498793; PMCID: PMC9039299.
5.Jiao L, Zhang G, Yuan Y, Cao L. A systematic review and meta-analysis of the correlation between cough variant asthma and mycoplasma pneumonia in children. Arch Med Sci. 2021 May 9;20(5):1579-1585. doi: 10.5114/aoms/130286. PMID: 39649255; PMCID: PMC11623152.
6.Huang W, Xu X, Zhao W, Cheng Q. Refractory Mycoplasma Pneumonia in Children: A Systematic Review and Meta-analysis of Laboratory Features and Predictors. J Immunol Res. 2022 Jun 26;2022:9227838. doi: 10.1155/2022/9227838. PMID: 35795531; PMCID: PMC9251082.
7.Zhan XW, Deng LP, Wang ZY, Zhang J, Wang MZ, Li SJ. Correlation between Mycoplasma pneumoniae drug resistance and clinical characteristics in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia. Ital J Pediatr. 2022 Nov 26;48(1):190. doi: 10.1186/s13052-022-01376-6. PMID: 36435821; PMCID: PMC9701416.
8.Xu M, Li Y, Shi Y, Liu H, Tong X, Ma L, Gao J, Du Q, Du H, Liu D, Lu X, Yan Y. Molecular epidemiology of Mycoplasma pneumoniae pneumonia in children, Wuhan, 2020-2022. BMC Microbiol. 2024 Jan 17;24(1):23. doi: 10.1186/s12866-024-03180-0. PMID: 38229068; PMCID: PMC10792977.
9.Li J, Luu LDW, Wang X, Cui X, Huang X, Fu J, Zhu X, Li Z, Wang Y, Tai J. Metabolomic analysis reveals potential biomarkers and the underlying pathogenesis involved in Mycoplasma pneumoniaepneumonia. Emerg Microbes Infect. 2022 Dec;11(1):593-605. doi: 10.1080/22221751.2022.2036582. PMID: 35094669; PMCID: PMC8865114.
10.Wang Y, Yu X, Liu F, Tian X, Quan S, Jiao A, Yang X, Zeng X, Jiao W, Qi H, Xu F, Li Q, Liu S, Xu B, Sun L, Shen A. Respiratory microbiota imbalance in children with Mycoplasma pneumoniae pneumonia. Emerg Microbes Infect. 2023 Dec;12(1):2202272. doi: 10.1080/22221751.2023.2202272. PMID: 37132354; PMCID: PMC10171136.
11.Wang C, Wen J, Yan Z, Zhou Y, Gong Z, Luo Y, Li Z, Zheng K, Zhang H, Ding N, Wang C, Zhu C, Wu Y, Lei A. Suppressing neutrophil itaconate production attenuates Mycoplasma pneumoniae pneumonia. PLoS Pathog. 2024 Nov 5;20(11):e1012614. doi: 10.1371/journal.ppat.1012614. PMID: 39499730; PMCID: PMC11567624.
12.Li M, Lu L, Xu H. Diagnostic value of miR-34a in Mycoplasma pneumoniae pneumonia in children and its correlation with rehabilitation effect. J Cardiothorac Surg. 2024 Sep 2;19(1):507. doi: 10.1186/s13019-024-02992-5. PMID: 39223566; PMCID: PMC11367975.
13.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
14.Ding X, Li S, Liu X, Zhan X, Wang Z, Wang M, Wu G. Study on the Correlation Between the Expression of NF-Ƙb in the Alveolar Lavage Fluid of Children with Severe Mycoplasma Pneumoniae Pneumonia, Its Clinical Characteristics, and Cellular Immunity. Infect Drug Resist. 2024 Jun 19;17:2469-2484. doi: 10.2147/IDR.S411361. PMID: 38915319; PMCID: PMC11194830.
15.Wang LP, Hu ZH, Jiang JS, Jin J. Serum inflammatory markers in children with Mycoplasma pneumoniae pneumonia and their predictive value for mycoplasma severity. World J Clin Cases. 2024 Aug 6;12(22):4940-4946. doi: 10.12998/wjcc.v12.i22.4940. PMID: 39109035; PMCID: PMC11238786.
16.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
17.Wang B, Liu J, Meng LJ, Liang J, Guan FJ, Dong C. Correlation between changes in hemorheology and the HIF-1/EPO pathway in children with Mycoplasma pneumoniae pneumonia. Clin Hemorheol Microcirc. 2025 Apr;89(4):348-355. doi: 10.1177/13860291251313591. Epub 2025 Mar 25. PMID: 40434092.
18.Leng J, Yang Z, Wang W. Diagnosis and Prognostic Analysis of Mycoplasma pneumoniae Pneumonia in Children Based on High-Resolution Computed Tomography. Contrast Media Mol Imaging. 2022 Apr 22;2022:1985531. doi: 10.1155/2022/1985531. PMID: 35542756; PMCID: PMC9054457.
19.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
20.Song Z, Han C, Luo G, Jia G, Wang X, Zhang B. Yinqin Qingfei granules alleviate Mycoplasma pneumoniae pneumonia by inhibiting NLRP3 inflammasome-mediated macrophage pyroptosis. Front Pharmacol. 2024 Aug 27;15:1437475. doi: 10.3389/fphar.2024.1437475. PMID: 39257401; PMCID: PMC11383775.
21.Fu S, Jia W, Li P, Cui J, Wang Y, Song C. Risk factors for pneumonia among children with coinfection of influenza A virus and Mycoplasma pneumoniae. Eur J Clin Microbiol Infect Dis. 2024 Jul;43(7):1437-1444. doi: 10.1007/s10096-024-04854-3. Epub 2024 May 24. PMID: 38789887.
22.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
23.Wang H, Zhang Y, Zhao C, Peng Y, Song W, Xu W, Wen X, Liu J, Yang H, Shi R, Zhao S. Serum IL-17A and IL-6 in pediatric Mycoplasma pneumoniaepneumonia: implications for different endotypes. Emerg Microbes Infect. 2024 Dec;13(1):2324078. doi: 10.1080/22221751.2024.2324078. Epub 2024 Apr 4. PMID: 38407218; PMCID: PMC10997354.
24.Guo P, Mei S, Wang Y, Zheng X, Li L, Cheng Y. Molecular typing of Mycoplasma pneumoniae and its correlation with macrolide resistance in children in Henan of China. Indian J Med Microbiol. 2023 Nov-Dec;46:100435. doi: 10.1016/j.ijmmb.2023.100435. Epub 2023 Aug 1. PMID: 37945129.
25.Bao X, Wang Q, Geng H, Yuan X. Correlation of prognostic values of IL-6 and PCT levels with the severity of pneumonia caused by Mycoplasma pneumoniae in children. Pak J Med Sci. 2025 May;41(5):1305-1310. doi: 10.12669/pjms.41.5.10448. PMID: 40469159; PMCID: PMC12130963.
26.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
27.Xue J, Fan Y, Luo R, Duan Y, Ai T, Wang L. Changes in airway resistance and its correlation with disease severity in children with Mycoplasma pneumoniaepneumonia. Transl Pediatr. 2025 May 30;14(5):939-946. doi: 10.21037/tp-2025-103. Epub 2025 May 27. PMID: 40519744; PMCID: PMC12163775.
28.Wei D, Zhao Y, Zhang T, Xu Y, Guo W. The role of LDH and ferritin levels as biomarkers for corticosteroid dosage in children with refractory Mycoplasma pneumoniae pneumonia. Respir Res. 2024 Jul 4;25(1):266. doi: 10.1186/s12931-024-02892-1. PMID: 38965565; PMCID: PMC11225272.
29.Wang J, Guo C, Yang L, Sun P, Jing X. Peripheral blood microR-146a and microR-29c expression in children with Mycoplasma pneumoniae pneumonia and its clinical value. Ital J Pediatr. 2023 Sep 13;49(1):119. doi: 10.1186/s13052-023-01500-0. PMID: 37705091; PMCID: PMC10500935.
30.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
31.Pavone S, Crotti S, D'Avino N, Gobbi P, Scoccia E, Pesca C, Gobbi M, Cambiotti V, Lepri E, Cruciani D. The role of Mycoplasma ovipneumoniae and Mycoplasma arginini in the respiratory mycoplasmosis of sheep and goats in Italy: Correlation of molecular data with histopathological features. Res Vet Sci. 2023 Oct;163:104983. doi: 10.1016/j.rvsc.2023.104983. Epub 2023 Aug 15. PMID: 37639802.
32.Li YT, Zhang J, Wang MZ, Ma YM, Zhi K, Dai FL, Li SJ. Changes in coagulation markers in children with Mycoplasma pneumoniae pneumonia and their predictive value for Mycoplasma severity. Ital J Pediatr. 2023 Oct 20;49(1):143. doi: 10.1186/s13052-023-01545-1. PMID: 37858230; PMCID: PMC10588045.
Copyright (c) 2025 Longxia Du, Jianping Wang, Zongxian Wu, Xianxin Lai, Xuanchen Qian
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.